Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2013—The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients and thereby allow doctors to better monitor and treat patients post-transplant. It is the first clinical validation study of this kind in Canada.
December 2013—New Purair 5 ductless fume hoods from Air Science USA feature a high level of operator protection where routine work is being carried out. The units exceed OSHA, ANSI, and all relevant international standards, operate at low noise levels, and recirculate rather than exhaust expensive conditioned or heated air into the atmosphere.
December 2013—Sequenom has announced a certified service provider program for the technical certification of selected laboratories offering research services using the Sequenom research-use-only MassArray system. Certifications cover the major research applications of the MassArray system, including iPlex genotyping, OncoCarta somatic mutation profiling, ADME PGx, and EpiTyper DNA methylation analysis.
December 2013—Quidel and Life Technologies announced that the FDA has granted 510(k) clearances to the Quidel Molecular Influenza A+B assay and the Quidel Molecular RSV+hMPV assay, both for use on the QuantStudio Dx Real-Time PCR instrument by Life Technologies.
December 2013—Randox’s two new controls, Acusera Liquid Assayed Chemistry Premium and Premium Plus, are designed to drastically cut the number of individual quality controls a laboratory needs to run in routine medical testing while providing clinically significant values for a wide range of analyzers at key decision points.
December 2013—Torrey Pines Scientific’s new EchoTherm stackable, programmable chilling incubators have a 27-L capacity and are Peltier based for heating and chilling. The incubators have no compressors or CFCs and are vibration free, making them ideal for protein crystallizations. Additional applications include incubating marine samples below room temperature, enzyme reactions and deactivations, hybridizations, ligations, and storing oocytes.
December 2013—Definiens AG, a health care company that advances personalized medicine through image-analysis and digital pathology solutions, and Advanced Cell Diagnostics (ACD), a provider of products and services for molecular pathology, announced the commercial launch of RNAscope SpotStudio, a custom-designed image-analysis software application for ACD’s RNAscope assays to detect and quantify RNA biomarkers.
December 2013—Skuldtech, a genomic biomarker company, has secured EUR 1 million in funding from Bpifrance (French public financing structure) as part of a project on Alzheimer disease that has received funding of EUR 8.6 million in total. The program is scheduled to last four years, with the first results expected in 2018.
December 2013—BioTheranostics announced that Mayo Clinic and Mayo Medical Laboratories will offer the company’s CancerType ID molecular cancer classification test to aid in the management of patients with metastatic cancer.
December 2013—Novartis announced a definitive agreement to sell its blood transfusion diagnostics unit to Grifols for $1.675 billion. The transaction is expected to be completed in the first half of 2014.
